A new study has now highlighted that certain gene defects that control of protein synthesis can either increase or decrease an individual's susceptibility to cancer and other diseases. Surprisingly, such genetic mechanisms can be responsible for cancer although the protein levels are normal, reveals the study that has been published in the journal, Science.
Directed by molecular biologist Davide Ruggero, Ph.D., of Fox Chase Cancer Center's human genetics program, the study attributed the protein defects to a critical glitch in the protein assembly line of ribosomes. This highlights the importance of proteomic research analyzing proteins.
'While defects in a number of genes are known to lead to cancer and disease, this opens up a new avenue of research,' Ruggero said. 'The DNA may be fine, but now we see another means by which the product it encodes can become defective.'
His new study shows that specific defects in RNA translation underlie a progressive disease called dyskeratosis congenita. It involves multiple organ systems and includes premature aging and increased susceptibility to cancer. The disease results from a gene mutation, Dkc1, that affects ribosome function.
Dyskeratosis congenita involves abnormal bone marrow leading to anemia, immune deficiency and infections; increased risk of various cancers, including lymphoma; and, starting as early as age 10, abnormalities of skin, nails and mucous membranes that resemble premature aging syndromes. The majority of patients are male.
The Fox Chase researchers used a variety of approaches to study the Dkc1 mutation in cells from humans with dyskeratosis congenita and in a genetically altered mouse model. Ruggero had previously developed this model, which faithfully recapitulates the human disease in mice.
The scientists found a decrease in production of certain proteins due to a specific defect in RNA translation that depends on a sequence called internal ribosome entry site (IRES). This particular sequence occurs in only some of the messenger RNAs that translate the DNA code into proteins.
'One of these proteins with decreased levels is governed by a gene, p27, that normally works to suppress tumors,' Ruggero pointed out. 'This could be a key explanation for the increased tumor susceptibility seen in patients with dyskeratosis congenita.
'Two other proteins found in the study, XIAP and Bcl-xL, are involved in regulating the normal dying off of cells, a process called programmed cell death or apoptosis. These particular proteins help cells survive during stress conditions, so a decrease in their levels could be important in explaining the high death rate of blood stem cells that leads to bone-marrow failure in patients.' The proteins Ruggero's new research identifies in connection with blood stem-cell depletion may also provide potential targets for developing new treatments for dyskeratosis congenita.
According to Ruggero, one long-term goal 'is to see if we can apply our knowledge of protein synthesis control to the discovery of therapeutic agents that target the translational machinery in cancer cells and human disease.'